India's Dr. Reddy's Is Set To Launch A Fourth Biosimilar - Pegfilgrastim
This article was originally published in The Pink Sheet Daily
Executive Summary
With filgrastim, rituximab and darbepoetin alfa already under its belt, Dr. Reddy's says it has seven more products - the bulk of which are thought to be copies of established monoclonal antibodies - in early development and preclinical testing.